GlassScriptPhysician profile
Rachel M Cameron
NPI 1831690254
$2,172.62
in general payments reported to CMS, 2019-2025
22 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $167 · 2023: $233 · 2024: $749 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.24 |
| Education | $322.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $387.11 | 2021-2025 | |
| Lilly USA, LLC | $266.82 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $197.41 | 2024-2025 | Veozah |
| Pfizer INC. | $178.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.32 | 2022-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $84.41 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Medtronic, INC. | $64.10 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.65 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $43.30 | 2023-2025 | Auvelity |
| Corcept Therapeutics | $30.00 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $29.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $24.27 | 2025 | Lithovue |
| Amgen INC. | $23.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.87 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2025 | Trintellix |
| Alkermes, INC. | $20.35 | 2022 | |
| Shield Therapeutics INC | $18.37 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.99 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2025 | |
| Exact Sciences Corporation | $17.26 | 2023 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $16.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.